Podcasts by OIS Podcast | Ophthalmology

With Positive Phase II Dry Eye Data in Hand, What’s Next for Aldeyra’s Promising Pipeline? from 2018-11-01T00:00

Aldeyra CEO and president Todd Brady shares the podcast mike with Dave McMullin, the former Shire executive who recently joined as senior vice president of corporate development and strategy. To...

Can Swiss Start-Up Ophthorobotics Develop a Robotics System to Deliver Intravitreal Injections? from 2018-10-31T00:00

In this podcast, CEO Franziska Ullrich explains how start-up Ophthorobotics is working to create a robotic system that can deliver in...

Eyedaptic CEO Jay Cormier Lays Out Start-Up’s Vision for Augmented Reality Visual Restoration Device from 2018-10-03T00:00

Eyedaptic president and founder Jay Cormier tells OIS Podcast about his company’s augmented reality visual aid for people with late-stage age-related macular degeneration, which it expects to start...

Simple Contacts CEO Joel Wishkovsky Says Start-Up’s App Could Upend Vision Care from 2018-09-26T00:00

Founder and CEO Joel Wishkovsky created Simple Contacts’ phone-based app to save contact lens wearers time and money when they need a new supply of lenses but not a new prescription. Ophthalmologis...

James Thimons, OD, Discusses Technology’s Positive Impact on Diagnosing and Treating Eye Disease from 2018-09-20T00:00

In this podcast, James Thimons, OD, delivers a comprehensive state of innovation in the treatment of eye disease. We recorded this interview in August immediately following the National Glaucoma So...

Glaukos COO Calcaterra Lays out Pipeline Plans Following iStent inject OK, Reacts to CyPass Recall from 2018-09-13T00:00

Chris Calcaterra, COO of Glaukos, revisits the company’s recent good fortune at the FDA, which approved its second generation iStent inject. What’s next for Glaukos? Calcaterra walks OIS Podcast li...

Louis Pasquale Discusses Eyenovia’s Trial, Other Causes of Glaucoma, and the Promise of Telemedicine from 2018-08-24T00:00

Louis Pasquale, MD, introduces us to the promising results of Eyenovia’s trial of its Microdrops latanoprost delivery platform....

Peter Menziuso, JJV President, North America Vision Care, Lobbying for Protections in the Contact Lens Rule from 2018-08-22T00:00

Peter Menziuso, president, North America Vision Care, Johnson & Johnson Vision, discusses J&J’s efforts to lobby a...

REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314 from 2018-08-15T00:00

REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changi...

Doug Foster, Chief Strategy Officer of Verana Health, Explains Plans to Replicate IRIS Partnership from 2018-08-08T00:00

Verana Health, once known as DigiSight, has been working to make AAO’s EHR database available to commercial partners. Now, the company plans to expand that model in healthcare. In this week’s OIS P...

Did You Miss OIS Retina (or Just Miss Being in Vancouver?) Hear Highlights from the Meeting Floor from 2018-08-02T00:00

OIS Podcast Host Tom Salemi Speaks with Investors Greg Grunberg, MD, and Firas Rihhal, MD, as well as OIS Contributors Richard Mark Kirkner and Bérénice Magistretti about some of the key takeaways ...

Skimming the Ocular Surface with TFOS’ Amy Gallant Sullivan and Purdue Researcher Chi Hwan Lee from 2018-07-18T00:00

This week the OIS Podcast skims the ocular surface with two interviews. First, we talk with Amy Gallant Sullivan, executive director of ...

Oyster Point Pharma CEO Nau Takes a Deeper Dive into Just-Released PEARL Trial Results from 2018-07-12T00:00

With Oyster Point Pharma announcing results from the Phase IIb PEARL study, company president and CEO from 2018-05-31T00:00

The last time we connected with Sean Ianchulev, MD, MPH, he shared Transcend's ultimately winning story. Now, he's the CEO and CMO of Eyenovi...

OIS Podcast Update on Dry Eye and MGD - What's Up at J&J, Oyster Point and Tear Film Innovations? from 2018-05-23T00:00

Hear the latest from OIS events as the OIS Podcast connects with Tom Frinzi and Joseph Boorady, the new le...

OIS Podcast Finds Out What's Next for Nicox and Zeiss in Two Talks with Michele Garufi and Jim Mazzo from 2018-05-16T00:00

Nicox has had quite a year, bringing two new ophthalmology projects to the market through partnerships with from 2018-05-10T00:00

The OIS Podcast returns with a double feature. Avedro CEO Reza Zadno talks about the company's latest $25 million round. Also, Bill Meury, CCO of Allergan, visits at OIS@ASCRS to talk about th...

Dry Eye Coach Hauser Speaks to How New Tech - Including Social Media - Can Bolster a Practice from 2018-04-04T00:00

Whitney Hauser, OD, has built a very visible brand as the Dry Eye Coach. With a website, podcasts, and sizable following on social media, she is building a platform that can help promote new treatm...

AcuFocus President Al Waterhouse Explains Company's Decision to Sell Kamra Inlay to Focus on IOLs from 2018-03-29T00:00

Al Waterhouse, President and COO of AcuFocus, tells the OIS Podcast why the company opted to sell its former flagship product to focus on IOLs. In this ...

SightLife Surgical CEO Monty Montoya Says Start-Up Is Building Out Cornea Market from 2018-03-22T00:00

SightLife Surgical in 2016 spun out of the well-known SightLife eye bank, capitalized by Flying L Partners. Two years late...

CEO David Muller Says Allotex Looks to Create Living Contact Lens with Corneal Allograft from 2018-03-14T00:00

The last time OIS Podcast talked with David Muller, he was leaving Avedro to start a new company. Two years later, Allotex has raised capital from a strategic investor and is preparing to enter cli...

AGTC's Washer on What it Means to Join BIO Board from 2018-02-28T00:00

Sue Washer, AGTC president and CEO, has joined the board of directors of the Biotechnology Innovation Organization (BIO). In this podcast, she talks about ...

Shire's Dempsey Highlights Global Leader's Early Bet in Optometry, Role in Upcoming OIS Launch from 2018-02-23T00:00

Robert Dempsey, head of Shire's global ophthalmics franchise, will be a headliner at next week's O...

Hear Details on Feb. 28 Dry Eye Dinner at SECO, Interview with J&J's Dry Eye Head, Joe Boorady from 2018-02-14T00:00

OIS - the Ophthalmology Innovation Summit - is introducing a new OIS Launch program to raise awareness and inform early adopters on recently launched and soon to be a...

New CEO Mattessich Brings in New Skills, Leadership to Help Ocular Therapeutix Reach Potential from 2018-02-07T00:00

New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vi...

Pixium Vision CEO Sees a Day When Wireless PRIMA Implant Could Bring Vision Back to AMD Patients from 2018-01-31T00:00

A veteran of bioelectronic medicine, Khalid Ishaque joined Pixium Vision four years ago after recognizing the promise of using implantable devices to restore vision. Today, the company is developin...

We Ask Analysts How Will Pharma and Medtech Companies Spend Billions in Repatriated OUS Profits? from 2018-01-25T00:00

Apple made headlines with a promise to spend repatriated dollars on R&D in the US. In this week’s podcast we talk with three Wall Street analysts to understand what we can expect to see from ph...

Life After the IPO: What Does Apellis Have Planned After Raising $170m from Public Investors? from 2018-01-17T00:00

Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atro...

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves from 2018-01-10T00:00

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what spec...

Oyster Point Pharma CEO Jeff Nau Taps Experience, Successful Network to Build Dry Eye Start-up from 2018-01-04T00:00

Oyster Point Pharma CEO Jeff Nau sheds some light on the new dry eye start-up, which is tapping much of the leadership and investment team that made Oculeve successful. He also talks about his own ...

Using AI to Improve Diagnosis of Disease from 2017-12-13T00:00

Michael Abramoff, MD, PhD, president, director, and co-founder of IDx, tells how the start-up is using artificial intelligence to better diagnose diabetic retinopathy. The company hopes to get FDA ...

Part II: OIS Co-chair Emmett Cunningham, Jr. Delivers Annual Overview on the State of Ophthalmology from 2017-12-06T00:00

In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, PhD, MPH, delivers a 360-degree revie...

OIS Co-chair Emmett Cunningham, Jr., MD. Delivers Annual Overview on the State of Ophthalmology from 2017-11-29T00:00

In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, delivers a 360-degree review of ophthalmology’s more promising pipelines.

Dry Eye Diaries: Hear Tales and Hopes from Leaders of Shire, Johnson&Johnson, and TearSolutions from 2017-11-21T00:00

In interviews at OIS@AAO, we talk with Robert Dempsey, global head of Shire’s ophthalmic business, about the international launch of Xiidra. Joseph Boorady, CEO and president of TearScience, lays o...

CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation from 2017-11-15T00:00

Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also reject...

Donnenfeld, MD, Talks Blue Sea PE Deal, OD/MD Collaboration, and Why OCLI Got CheckedUp from 2017-11-07T00:00

Eric Donnenfeld, MD, founding partner of Ophthalmology Consultants of Long Island, explains how his practice will use a capital infusion from growth equity firm Blue Sea Capital. Dr. Donnenfeld als...

OIS Co-Chair Emmett Cunningham Walks through the Upcoming OIS@AAO Agenda, Reveals New Ways to Engage from 2017-11-01T00:00

OIS co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, talks about OIS’ evolution over nearly a decade of meetings. The addition of Breakfast Breakout Sessions and Master Classes has opened opportuni...

Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors from 2017-10-25T00:00

Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to mo...

Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease from 2017-10-18T00:00

Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an ey...

What’s Next PanOptica? We Ask CEO Chaney from 2017-10-11T00:00

CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specia...

ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor from 2017-10-04T00:00

With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and ...

Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments from 2017-09-28T00:00

Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as c...

Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments from 2017-09-20T00:00

Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or into the partnership at Hatteras Ventu...

Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop from 2017-09-13T00:00

Accomplished ophthalmologist Mark Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blume...

What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Roberts from 2017-09-06T00:00

In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade a thriving ophthalmology practice to serve as chief m...

Imperial College’s Dr. Cordeiro Explains How DARC May Bring Early Light to Disease, Shorten Trials from 2017-08-28T00:00

M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, shares details of the institute’s detection of apoptosing retinal cells (DARC) scan – which ...

Why Did Charles Semba, MD, Switch Specialties and How Did He Find a Home in Ophthalmology? from 2017-08-23T00:00

Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and mo...

OIS@ASRS Co-Chairs Give High Marks and Hopes for Innovators Looking at the Back of the Eye from 2017-08-16T00:00

OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS presi...

Should You Be at OIS@ASRS on Thursday? Take an Insider Look at the Agenda with Emmett Cunningham from 2017-08-08T00:00

OIS Co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, managing director, Clarus Funds, walks us through the agenda of Thursday’s OIS@ASRS. What areas of retina will dominate the headlines for the ne...

What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans from 2017-08-08T00:00

Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashl...

Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian from 2017-08-02T00:00

Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patient...

Double Shot: Two Leading Ophthalmologists Discuss the Impact Innovation Is Having on Eye Care from 2017-07-26T00:00

In two recent interviews, Elizabeth Yeu, MD, Virginia Eye Consultants, and Richard Lewis, MD, Sacramento Eye Consultants share how innovation is changing how they treat patients. Reimbursement, mar...

Investor, Executive Shine Light on Private Equity’s Growing Interest and Influence in Ophthalmology from 2017-07-18T00:00

In this OIS Podcast, David Alpern, partner at Varsity Healthcare Partners, and Brent Wilde, president of Minnesota Eye Consultants, offer complimentary perspectives on Private Equity’s impact on op...

Sun Pharma’s St. Peter Outlines Company’s Ambitious Plan to Build Ophthalmology Pipeline from 2017-07-11T00:00

Jerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building a broad pipeline to treat eye disease including dry eye and ocular pain. In...

Alcon's Attias Touts Growing Pipeline Including Progress in Glaucoma and Google Projects from 2017-07-05T00:00

Laurent Attias, head, strategy, BD&L and M&A, reports on progress on Alcon’s project with Google and its advancing glaucoma portfolio. Attias says Alcon is “open for business” and continuin...

NEA's Behbahani, with New Fund to Invest, Discusses VC's Strong Interest in Ophthalmology from 2017-06-27T00:00

After capturing lighting in a bottle with Oculeve, Ali Behbahani, MD, partner of New Enterprise Associates, recalls the experience with the Dry Eye start-up and lays out his plans for investing in ...

Implandata Co-Founder Outlines Next Step as Company Scores CE Mark for Continuous IOP Monitoring Device from 2017-06-21T00:00

Max G. Ostermeier, MBA, co-founder and general manager of Implandata Ophthalmic Products GmbH, charts a course for the company after securing CE mark for its EYEMATE eye pressure measurement system...

Mynosys CEO Hendrick Lays Out Next Step for Zepto Following Positive FDA, Strong OUS Launch from 2017-06-14T00:00

Mynosys Cellular Devices CEO and president John Hendrick lays out his company’s plan to roll out Zepto in the US. The firm has reported strong demand in OUS markets, and Hendrick anticipates it wil...

Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients from 2017-06-07T00:00

Eric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and it enables me to spend more tim...

COO Tom Mitro Discusses Aerie’s Preparation for Rhopressa Launch, Updates OIS@ASCRS on Pipeline from 2017-05-31T00:00

In this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says new hires brought on to prepare for likely commercial sale of Rhopressa bring new life and energy into a company hitting its stride....

CEO Ludwin Monz Discusses Zeiss’ Important Management Hires, SMILE, and the Future of Diagnostics from 2017-05-24T00:00

Ludwin Monz, PhD, President and CEO of Carl Zeiss Meditec explains why the ophthalmology leader brought in new senior leadership. He also reviews the company’s recent product approvals and gives an...

Alice Epitropoulos, MD, on How Xiidra, TrueTear, and Other Treatments Impact Practices, Patients from 2017-05-18T00:00

Now that Shire’s Xiidra claims a 20% market share, find out how it’s impacting the practice. Alice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to expla...

CEO Ram Rao Discusses Juvene, the Rise of Presbyopia, and How LensGen Raised $21 million from 2017-05-10T00:00

LensGen CEO Ram Rao discusses his company’s $21 million Series A and the increased interest in presbyopia.

In an Insightful Wrap-up, OIS Co-chairs Share the Top Takeaways from another Successful OIS@ASCRS from 2017-05-07T00:00

Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following a successful OIS@ASCRS.

Can OIS Help Make Myopia Great Again? Co-chair Kliman Discusses Inventive New Panel, Opportunities from 2017-04-27T00:00

Gil Kliman, managing director at InterWest Partners, reviews his role at the upcoming OIS@ASCRS, including an overview of anterior segment innovation and a discussion on lower myopia.

Award Winner Korroch Explains How Eye Banks Have Worked to Ensure Supply Exceeds Demand from 2017-04-20T00:00

Longtime eye bank executive David Korroch, chief executive officer, Lions Medical Eye Bank, explains how eye banks have worked hard to meet – and even exceed – the demand for donated tissue. Korroc...

What’s the Difference between Creativity and Innovation? Blumenkranz Answers That and Much More from 2017-04-12T00:00

Mark S. Blumenkranz, MD, H. J. Smead Professor of Ophthalmology, Emeritus, delivers his State of Innovation address. You can guess what his assessment is, but we’ll give you a hint. It involves coo...

OIS Co-Chair Bill Link Walks Us Through OIS@ASCRS May 4 Agenda and Introduces Flying L Partners from 2017-04-05T00:00

OIS Co-Chair William J. Link, PhD walks us through OIS@ASCRS’ May 4 agenda, which takes place in LA. Link also explains why he Andy Corley and Richard Lindstrom, MD, formed Flying L Partners. Hear ...

Prolific Investigator Thompson Gives His Take on SMILE, Cross-Linking, Oculeve, and Other Innovations from 2017-03-29T00:00

From his clinic in South Dakota, Vance Thompson has served as an investigator in over 60 clinical trials. Thompson taps this experience to shed some light on new innovations being brought forth by ...

Co-author Thomas Albini, MD, Explains Why Eye Docs Wrote NEJM Paper to Expose Stem Cell Injuries from 2017-03-22T00:00

In 2015, three patients who had a stem cell mixture injected in their eyes were severely injured. To try to prevent this from happening again, their treating physicians reached out to the FDA and c...

Nancy Lurker Discusses Bringing Her Commercial Experience, Insights to Drug Delivery Upstart pSivida from 2017-03-15T00:00

Newly appointed President and CEO Nancy Lurker explains why she took over as CEO and President at pSivida and gives details on the company’s early clinical testing results in the recurrence of uvei...

We Ask Dick Lindstrom What Practice Consolidation May Mean for Ophthalmology, Innovation (Pt. 2) from 2017-03-08T00:00

Last month, Minnesota Eye Consultants announced it was working with private equity investor Waud Capital to create an entity that could build a national eye care provider. In part two of our interv...

Dick Lindstrom Tells us why Minnesota Eye Consultants Partnered With a Private Equity Firm (Pt. 1) from 2017-03-01T00:00

Consolidation is coming to ophthalmology. Last month, Minnesota Eye Consultants agreed to partner with a private equity group to expand beyond the Twin Cities. In the first of a two-part podcast, f...

Apellis CEO Delivers Some Hopeful Pipeline News, and Offers a Cautionary Note on Immigration Debate from 2017-02-23T00:00

Cedric Francois, co-founder, CEO, and president of Apellis delivers an update on his start-up’s promising complement therapies. He also shares why he joined other Biotech CEOs and VCs in speaking a...

Eyes Up! NEI Challenges “Solvers” to Create 3D Retina Organoid that Could Aid Research from 2017-02-15T00:00

On February 28, the National Eye Institute will host a webinar to introduce its 3D Retina Organoid Challenge. Its objective is simple: use $1 million in prize money to encourage researchers from mu...

Abbie Celniker Shares Her View of Pharma, Ophthalmology from High-flying Third Rock Ventures from 2017-02-09T00:00

Ophthalmology CEO turned VC Abbie Celniker, now a partner at Third Rock Ventures, discusses her role at the firm and reveals how it will invest its new $616 million fund.

Can Presbyopia Therapies Deliver an Encore with its Own Vision-Correcting Eye Drops? from 2017-02-02T00:00

With Novartis’ acquisition of Encore Vision setting the standard, CEO Jim McCollum and CSO Jerry Horn, MD, tell the tale of Presbyopia Therapies, a small start-up that is working to develop “lifest...

Novartis Sees Clear Opportunity in Encore Vision’s Unique Approach to Correcting Presbyopia from 2017-01-27T00:00

Frederic Guerard, head of Novartis’ ophthalmology franchise, explains why the global giant was the last strategic standing in the competitive bidding to acquire the promising, but very early stage,...

Looking Beyond the Tweets: What Trump’s Pharma Pricing Pledge Might Mean for Ophthalmology from 2017-01-18T00:00

The threat of Medicare clamping down on drug prices has never loomed larger. Sanford Bernstein’s Ronny Gal and Liav Abraham of Citi gauge the risk and explain how ophthalmology drug companies might...

Novaliq’s Positive Phase II Dry Eye Results Present Break from Disappointing Clinical Trial Season from 2017-01-12T00:00

Christian Roesky, PhD, joins the OIS Podcast to explain why he became the new CEO and managing director of Novaliq GmbH, a specialty pharma company with a novel drug delivery platform technology th...

EyeGate Pharma Discusses Early Clinical Trials Success, Promising Pipeline, and Partnership Payouts from 2017-01-06T00:00

EyeGate CEO Stephen From reports positive results of Phase Ia/IIb trials of EGP-437, regulatory progress for its Ocular bandage gel, and potential fundraising plans.

What Now? What Does Ophthotech’s Disappointing Phase III Results Mean for Wet AMD, VEGF and PDGF? from 2016-12-16T00:00

KOLs, CEOs, and analysts say Ophthotech’s disappointing Fovista trials alter the landscape for companies developing new treatments for wet AMD. And all agree, the biggest losers in all of this are ...

Can Lighting Strike Twice? SARCode’s Co-Founder Gadek Takes Helm of Promising Dry Eye Start-up from 2016-12-07T00:00

Three-year-old TearSolutions hopes to pen a strong sequel to SARCode’s successful tale of a start-up developing the next new treatment for Dry Eye Disease. Tom Gadek, co-founder of SARCode, develop...

Andrew Chang Discusses His Move to Lead Global Sales of Zeiss Meditec’s Ophthalmic Devices from 2016-11-30T00:00

Carl Zeiss Meditec continues to add top talent. Andrew Chang, who managed US sales at B&L, joins the growing group bringing him together with Unit Head Jim Mazzo.

What Are Tom Frinzi’s Plans after J&J Acquires AMO? Frinzi Talks J&J, Symfony, and Much More from 2016-11-22T00:00

This has been a busy year for Thomas Frinzi, senior vice president of Abbott’s vision business. He took the helm of Abbott Medical Optics in January. In July, the FDA approved the company’s promisi...

OIS Editorial Roundtable: What Impact Will a Trump Administration Have on Ophthalmology? from 2016-11-16T00:00

The election of Donald Trump had an immediate impact on our OIS Index. OIS writers and editors dig deeper, discussing what the long-term impact could be on drug prices, regulation and the ophthalmo...

Carl Zeiss’s Jim Mazzo Talks About Failing Fast, the Reply All Button and Reaching the Customer from 2016-11-09T00:00

Ophthalmology veteran Jim Mazzo has led companies of every size. Hear how those experiences are guiding him in his new post at Zeiss.

How it All Began. Allergan’s Herbert Shares Details of His Contribution to Ophthalmology’s Origins from 2016-11-01T00:00

Gavin S. Herbert recalls what it took to make Allergan a success and how he helped build a Medtech industry in Southern California.

David Pyott on Growing Allergan, Defending Against Acquisitions, and How the Next Chapter Will Read from 2016-10-27T00:00

After being honored by OIS last week in Chicago with an OIS Innovator Award, David Pyott, former Allergan CEO, sits down with OIS-TV to discuss rebuilding Allergan, fending off Valeant’s acquisitio...

Live (sort of) from Chicago: OIS Podcast Brings You the Voices of OIS@AAO from 2016-10-20T00:00

This OIS Podcast brings a bit of OIS@AAO to your laptop and smartphone. Hear from a few of the leaders in ophthalmology including executives from Allegro Ophthalmics, Avedro, LacriScience, Ocular T...

Introducing Our Newest Tool – the OIS Index from 2016-10-12T00:00

OIS has partnered with Michael Lachman of EyeQ Research to create a vital new stock index of ophthalmology companies. This new tool will enable us to deliver broader insights and stronger analysis ...

OIS Founder&Co-Chair Emmett Cunningham Jr. Tells Us What to Watch for Next Week in Chicago from 2016-10-05T00:00

Emmett T. Cunningham Jr., MD, PhD, MPH, partner at Clarus, runs through the revamped agenda of OIS@AAO. Go to OIS.net to view the agenda and to register.

Hear How Preceyes Will Help Usher Robotics into Ophthalmic Surgery from 2016-09-28T00:00

This month, a surgeon performed ophthalmology’s first robot-assisted surgery – a membrane peel. Prof. Marc de Smet, chief medical officer of Preceyes, a Dutch start-up shares the company’s history ...

Behind the Deal: McEvoy On Where Will AMO Fit into J&J&What the Deal Means for Eye Care from 2016-09-21T00:00

Ashley McEvoy, group chairman of J&J’s Vision Group, says the combination of consumer and surgical businesses will create a powerful new force in ophthalmology.

Live (sort of) from Copenhagen: OIS Podcast Hits the High Points of ESCRS and EuRetina from 2016-09-15T00:00

Copenhagen was the epicenter of the ophthalmology last week as several clinical meetings including ESCRS, EuRetina, and EuCornea convened in the city. OIS Podcast reports from the hallways, meeting...

Xiidra Prior to Shire: How SARcode Took on the Odds to Pursue a New Treatment for Dry Eye from 2016-09-08T00:00

Shire scored a huge win this summer by securing FDA approval of Xiidra. Hear from three principals of SARcode Bioscience, the start-up that discovered the Dry Eye treatment – then known as lifitegr...

A note from OIS Podcast from 2016-09-01T00:00

CEO John Kilcoyne Reviews ReVision’s Success with the FDA&its Plans to Roll Out Raindrop from 2016-08-18T00:00

ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.

Live from the Floor of OIS@ASRS: Co-Chair Bill Link on What Made the Day Work So Well from 2016-08-11T00:00

Live from the floor of OIS@ASRS: Co-chair Bill Link on what made the day work so well. The marriage of OIS with ASRS started strong. Hear ophthalmology veteran Bill Link on why the back of the eye ...

What Will Carl Zeiss Meditec’s New Ophthalmology Unit Look Like? We Ask Jim Mazzo. from 2016-08-03T00:00

Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportuni...

Clearside Biomedical Finds the Public Markets Despite Diminished Interest in Sector from 2016-07-26T00:00

Clearside CEO Dan White says the days when ophthalmology IPO candidates could do no wrong are over. Still, the company staged a successful IPO to help further development of its SCS microinjector t...

Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications? from 2016-07-20T00:00

Allegro Ophthalmics’ executive team boasts a successful pedigree that began with starting ISTA and taking it public. Now, Vicken Karageozian, MD, president and CMO, says the company is six months a...

Godspeed Xiidra. Shire’s Robert Dempsey Introduces the Newest FDA-Approved Treatment for Dry Eye. from 2016-07-12T00:00

Robert Dempsey joined Shire to build a new ophthalmology unit. Until now, the division had been mostly theoretical with no products to sell. Now, the brand building is over. Shire officially has en...

What Drives Innovators? Pioneer Mark Humayun, MD, PhD, Shares His Story&Vision for Ophthalmology from 2016-07-06T00:00

Over two decades ago, Mark Humayun - who will co-chair our upcoming OIS@ASRS - helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we ...

A Walk Down Wall Street: Two Analysts Tell You What to Expect From the Markets in the Coming Months from 2016-06-29T00:00

Pfizer. Allergan. Valeant. Bausch & Lomb. The ophthalmology sector is rich in big deals that happened, didn’t happen, and could happen. How does the sector – and the market overall – look to an...

Steven Vold, MD, Sees Enormous Potential in Coming Tide of IOLs, Diagnostics&Potential New Drugs from 2016-06-22T00:00

Steven Vold, MD, sees huge advances in MIGs treatment, drug delivery and new neuroprotective compounds that could help treat glaucoma and perfect vision.

Aldeyra CEO Highlights Clinical Trial Success of Possible Treatments for Conjunctivitis, Uveitis from 2016-06-15T00:00

Once a VC, Todd Barry decided to assume the CEO and president post of Aldeyra, a start-up with a promising – and potentially far-reaching – technology for treating ocular and other diseases.

Ludwin Monz, PhD, Discusses Zeiss, its Legacy&Where it Pursues New Innovation from 2016-06-08T00:00

Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies.

Bausch&Lomb’s CMO Cal Roberts on How He Uses His MD&Experience to Build the Right Tool Kit for Ophthalmologists from 2016-05-31T00:00

Bausch & Lomb’s chief medical officer Calvin Roberts, MD, still thinks like a doc when he’s helping to steer the company’s strategy. Hear how he sees B&L making life simpler for ophthalmolo...

Dempsey on Building the Shire Brand in Ophthalmology from 2016-05-24T00:00

Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “th...

OISPodcast@ASCRS - Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise from 2016-05-19T00:00

Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business...

What the Heck Happened at OIS@ASCRS? from 2016-05-15T00:00

The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn...

Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD&Other Eye Disease from 2016-05-03T00:00

Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would...

Sun Ophthalmics Looks to Build a Brand-New Business in the US from 2016-04-28T00:00

Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how ...

Avedro’s Long Wait for FDA Approval is Over from 2016-04-20T00:00

The FDA approved Avedro’s New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive sur...

What are Allergan’s Next Steps? from 2016-04-13T00:00

The near merger between Pfizer and Allergan clearly was financially motivated. But the deal promised to bring Pfizer’s firepower to ophthalmology. What does the annulment of the deal mean for our s...

KOL Corner: Can Complement Inhibitors Treat Macular Degeneration? from 2016-04-06T00:00

The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field ma...

Frinzi shares a bit of his plans for AMO from 2016-03-29T00:00

Following his successful exit from WaveTec, Tom Frinzi joined Abbott as a senior vice president and head of AMO. In this exclusive interview with OIS, Frinzi shares his motivations and what he’d li...

Can Apellis Find a Way to Inhibit the Complement System&Treat Intermediate AMD? from 2016-03-24T00:00

Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling...

Lewis Handicaps MIGS Market and Explains Glaucoma’s Emergence from 2016-03-16T00:00

Glaucoma specialist Dr. Richard Lewis says glaucoma was once the “boring step sister” of the ophthalmology world. But now the chief medical officer of Aerie says the rise in devices and drugs has m...

VisionCare Battling Back against Macular Degeneration from 2016-03-09T00:00

CEO Wolfgang Tolle joined VisionCare last year to move the company into the commercial stage. Now with long-term data and reimbursement in place, the firm is making a strong commercial push.

Heier Talks Anti-Angiopoietin Programs, Clinical Trials&Red Sox from 2016-03-02T00:00

Jeff Heier, MD, is the Director of the Vitreoretinal Service and the Director of Retina Research at Ophthalmic Consultants of Boston (OCB) gives an update from the Angiogenesis conference about the...

KOL Corner: Alcon, Transcend&Glaucoma 360 from 2016-02-25T00:00

Glaucoma once might have been a boring or sleepy sub-specialty of ophthalmology, but recent technical advances and significant bets placed by large strategics including Alcon’s planned acquisition ...

What Does the Leadership Shuffle Mean for Ophthalmology? from 2016-02-18T00:00

The combination of Pfizer and Allergan certainly creates some waves in ophthalmology. But did these choppy waters have anything to do with recent leadership changes in ophthalmology?

EyeGate Finds New Paths to Dollars, Deal from 2016-02-11T00:00

EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the compa-ny needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to th...

Muller Explains Departure from Avedro; Opportunity in New Venture from 2016-02-03T00:00

David Muller came close to writing the final chapter of Avedro’s push to have corneal cross-linking approved by the FDA. But he opted to leave the company before the final approval came through to ...

Inotek’s Southwell and McVicar Have Designs on Treating Glaucoma from 2015-12-16T00:00

Inotek CEO David Southwell and William K. McVicar Ph.D. Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers.

Emptying the OIS Reporter’s Notebook After OIS@AAO from 2015-12-09T00:00

OIS Correspondents Michelle Dalton and Richard Kirkner pool their insights on the most compelling sights and insights of OIS, Subspecialty Day and AAO. The two scribes opine on exiting new disease ...

Where Will `Pfizergan’ Fit in Ophthalmology from 2015-12-01T00:00

Allergan has been a pillar of the ophthalmology sector for decades, so it’s merger with Pfizer is creating some concern along with great optimism. But ophthalmology leaders also see the opportunity...

Aura Biosciences Offers Hope for Ocular Melanoma from 2015-11-23T00:00

Elisabeth “Eli” de los pinos was enjoying her job at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for th...

A Rundown of a Record-setting OIS from 2015-11-19T00:00

The Ophthalmology Innovation Summit hit it big in Las Vegas prior to the industry’s American Academy of Ophthalmology Annual Meeting. With close to 1,000 registered attendees, OIS@AAO brought innov...

Celniker Gets Eleven Bio Ready For OIS and Conference Season from 2015-11-09T00:00

Eleven Biotherapeutics last spring issued some disappointing news when its leading project, EBI-005 didn’t fare well in a Phase III trial for Dry Eye. However, the company’s AMP-Rx platform is chug...

Ora’s Ousler Delves Deep into Dry Eye from 2015-11-02T00:00

Dry eye remains one of the more dynamic sectors of ophthal-mology with Shire’s recent news about its lead Lifitegrast product moving toward FDA approval. Ora knows Dry Eye better than most, and Vic...

Muller on the FDA, PIXL and Dairy Farms from 2015-10-28T00:00

Avedro’s long saga with the FDA continues. Last week, the firm resubmitted the NDA for its riboflavin ophthalmic solution/KXL System, which should be the final step toward the company securing FDA ...

Biogen’s High Hopes For Gene Therapy, Ophthalmology from 2015-10-21T00:00

In July, Biogen signed a potential $1 billion-plus deal with Applied Genetic Technologies Corp. The deal, which included an equity investment, centered around AGTC’s leading gene therapy programs d...

Understanding Market Cycles: When Could Biotech UnBoom? from 2015-10-13T00:00

David Nierengarten, Managing Director, Wedbush Securities, explains how public market cycles could hit biotech and ophthalmology companies.

Can Spark Phase III Results Ignite Gene Therapy? from 2015-10-08T00:00

Jeffrey D. Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses the successful Phase III trial of its lead candidate, SPK-RPE65, was able to improve functional vision in patients with a ra...

Implandata's Hands-On Approach To Tracking IOP from 2015-09-30T00:00

Implandata Ophthalmic Products GmbH is putting the task of tracking intraocular pressure into the hands of patients. Company Co-founder and General Manager Max G. Ostermeier shares the story of Eye...

Sadri: How MIGS And Other New Tech May Change His Practice from 2015-09-23T00:00

Ehsan Sadri, M.D., FACS, FAAO discusses the impact MIGS will have on ophthalmology practices and offers his insights on how ophthalmologist will handle pressure from Obamacare and other external fo...

OcuSciences Hopes to Give Early Warning on Ocular Disease from 2015-09-16T00:00

Kurt Riegger, President and COO of OcuSciences, tells a start-up’s tale. OcuSciences’ OcuMet Beacon is being developed to give optometrists and ophthalmologies the ability to see the onset of disea...

Imprimis’ Baum on Disrupting Compound Pharmacies from 2015-09-09T00:00

Imprimis Pharmaceuticals is disrupting the compound pharmaceutical industry, a segment of health care that’s undergoing significant regulatory upheaval. The company’s line of ophthalmology drugs co...

Opthea Exploring Different Approach To Treating Wet AMD from 2015-08-31T00:00

Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin ...

Makower: Making Medtech Bigger, Stronger, Faster from 2015-08-26T00:00

Josh Makower, MD, literally wrote (or co-wrote) the book on Medtech Innovation. Makower is a general partner in New Enterprise Associates most recent fund, but he’s worked with the firm as a Ventur...

ClarVista’s Two-Part Strategy To Premium IOLs from 2015-08-19T00:00

CEO Paul McLean and Medical Director Malik Kahook, MD, explain how they’ll bring Harmoni to the IOL market.

CEO Tom Burns Has Even Bigger Plans For Glaukos from 2015-08-12T00:00

MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already command-ing reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billi...

Year 1: What OIS Podcasts Were Most Popular? Part Two from 2015-08-05T00:00

We’re thrilled to be celebrating the one-year anniversary of the OIS Podcast. We hope you enjoyed these tales of innovation as much as we have. To celebrate milestone we reveal and review the inter...

Year 1: What OIS Podcasts Were Most Popular? from 2015-07-29T00:00

We’re thrilled to be celebrating the one-year anniversary of the OIS Podcast. We hope you enjoyed these tales of innovation as much as we have. To celebrate milestone we reveal and review the inter...

A Favorite From The OIS Podcast Stack from 2015-07-21T00:00

Oculeve’s stunning acquisition by Allergan last week led us back to a conversation we had with Mark S. Blumenkranz, MD, Professor & Chairman of the Department of Ophthalmology, Stan-ford Univer...

Clarus Delivers Good News With $500m Fund from 2015-07-14T00:00

OIS Co-Chair Emmett Cunningham explains how Clarus will invest new $500m fund in ophthalmology and beyond.

The Ophthalmology Innovation Summit w...

Oculeve Open Ups, Just a Little, on OD-01 from 2015-07-08T00:00

Oculeve CEO Michael Ackermann Talks About Allergan’s Big Move in Dry Eye.

The Ophthalmology Innovation Summit was created to facilitate meaningf...

Hear Bausch&Lomb’s Ophthalmology Play Book from 2015-06-30T00:00

Bausch &Lomb Surgical’s Andrew Chang Has Big Plans in Ophthalmology Surgical.

The Ophthalmology Innovation Summit was created to facilitate ...

A discussion of Allergan’s legacy and future in Medtech Ophthalmology from 2015-06-23T00:00

Hear from Allergan’s Past and Future: Highlights of interviews with Brent Saunders and Gavin Herbert.

Here is How Big Companies Innovate from 2015-06-15T00:00

Leaders of Alcon, AMO, Valeant and Zeiss Discuss the Role of Innovation in their Success.

Hear How Valeant Innovates, Invests and Acquires from 2015-06-10T00:00

Valeant CEO J. Michael Pearson tells OIS attendees how the controversial company finds new technologies.

The Ophthalmology Innovation Summit was...

Transcend Medical Ready To Make Move In MIGs from 2015-06-02T00:00

Transcend Medical CMO Sean Ianchulev provides update on COMPASS trial and shares company’s plan for the FDA.

Borrmann Gives View Into AMO’s Innovation Cycle from 2015-05-26T00:00

Leonard Borrmann, head of R&D at AMO, explains how the company encourages “failing forward” and other innovative qualities to creating new vision devices.

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneur...

Alternative Financing Approaches from 2015-04-21T00:00

As venture investors shift to later stages, start-ups will have to look harder for new sources of innovation. A panel at OIS@ASCRS discusses how new sources of capital can sustain the creation of n...

PowerVision’s Cheskin discusses the potential of the company’s accommodating IOL, FluidVision from 2015-04-13T00:00

For 10 years PowerVision has been advancing its accommodating IOL, Flu-idVision. Co-Founder, CEO and President Barry Cheskin explains how the company has kept its focus on someday capturing a huge ...

Alphaeon’s Grant Explains Innovative New Model from 2015-04-07T00:00

Alphaeon is tapping physicians for unprecedented involvement in finding and funding new treatments. Hear how the company sees the future of health care.

The Ophthalmology Innovation Summit was ...

Talley Rostov Works to Improve Global Vision from 2015-03-10T00:00

Seattle Ophthalmologist Audrey Talley Rostov explains how she became involved in an international movement to end corneal blindness.

The Ophthalmolo...

Blumenkranz Shares His Success, Failures And New Opportunities For Ophthalmic Innovators from 2015-03-02T00:00

Mark Blumenkranz, MD, has had a hand in starting many exciting biotech, medtechs and digital health companies. Hear how his innovative process begins and what he’s doing to help foster new ideas in...

Alcon’s Plan For WaveTec’s ORA System from 2015-02-24T00:00

Alcon’s Warner, Frinzi Discuss the WaveTec Vision Acquisition Details

The Ophthalmology Innovation Summit was created to facilitate meaningful i...

CEO Russ Trenary Discusses InnFocus’ Push into the Competitive MIGs Market from 2015-02-17T00:00

Description: Ophthalmology Industry Veteran Russ Trenary Reveals How InnFocus Intends to Capture a Piece of the Growing MIGs Market.

The Ophthalmolo...

Ophthalmology By The Numbers With Jon Norris of SVB from 2015-02-09T00:00

Jon Norris, Managing Director of Health Care at Silicon Valley Bank, gives a sneak peak on his coming report on the health care sector and discusses why ophthalmology continues to be a strong sourc...

DigiSight Puts Eye Care in Patients’ Hands from 2015-02-03T00:00

DigiSight President and CEO Doug Foster explains how mobile technologies like his company’s SightBook app can help save patient vision and help the pharmaceutical industry develop new ophthalmology...

Vance Thompson, MD, Speaks to Importance of Patient “Experience” in a successful practice. from 2015-01-27T00:00

Vance Thompson, MD, sees patient “Experience” as a secret weapon in building a successful practice. He shares the steps his group takes to ensure patient service is as big a draw as new technologie...

A multi-generational look at ophthalmology with Dr. George O. Waring IV from 2015-01-20T00:00

The ophthalmology patient base often is seen as a single, monolithic mass. But different generations have different needs and must be approached appropriately, says Dr. George O. Waring IV.
Listen

Second Sight Fulfills Dream from 2015-01-13T00:00

Second Sight President & CEO Robert Greenberg, MD, PhD looks back on Sec-ond Sight’s long road to getting FDA approval for Argus II and considers the path not taken.

Eleven’s Celniker Talks Leadership, Public Markets, and Phase III Dry Eye Trials from 2015-01-06T00:00

Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead Dry Eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, t...

Cunningham: 2015 Could Be A Big Year For Ophthalmology from 2014-12-16T00:00

OIS co-chair Cunningham delivers a high altitude review of the much sought after "Year in Review" report he delivers at each event. In this review, Cunningham touched upon his hopes for t...

TearScience CEO Willis Explains Dry Eye Disease’s Emergence from 2014-12-09T00:00

TearScience CEO Tim Willis discusses the emergence of Dry Eye Disease and details how his company’s diagnostic and treatment for a source of the condition could help meet the increasing interest fr...

Alimera CEO Myers Shares Lessons From Iluvien FDA Approval from 2014-12-02T00:00

The FDA turned away Alimera Sciences’ bid to market Iluvien as a treatment for diabetic macular edema three times before finally giving the green light. President & CEO Dan Myers shares what ke...

Opening The Door For Premium IOLs from 2014-11-24T00:00

OIS stalwart Jack Holladay, MD shares details on the work of a task force com-prised of representatives from the American Academy of Ophthalmology and the Food and Drug Administration charged with ...

Ocular Therapeutix Starting to Sprint from 2014-11-17T00:00

Prior to starting Ocular Therapeutix, Amar Sawhney, already a successful medtech entrepreneur was a bit concerned about the unique challenges posed by the ophthal-mology sector. Today, with the com...

Alcon Head Jeff George Lays Out Vision from 2014-11-11T00:00

Jeff George, President & Global Head of Alcon, shares his optimism for the oph-thalmology sector with attendees at the recent Ophthalmology Innovation Summit in Chicago. George explained what o...

How Thoughtful Consolidation Can Benefit Ophthalmology from 2014-11-03T00:00

At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, Presi-dent & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Med...

How Alcon and Google Could Change the Contact Lens from 2014-10-28T00:00

At the recent Ophthalmology Innovation Summit in Chicago, Google and Alcon executives shared the origins and potential outcomes of the partnership between the two com-panies. Initially, they hope t...

NASA-Backed Entity Enlists Industry To Battle Eye Disorders Caused By Space Travel from 2014-10-21T00:00

Dorit B. Donoviel, PhD, Deputy Chief Scientist and Industry Forum Lead of the National Space Biomedical Research Institute, and Randy McDonald, Founder and President of the Magnum Group, discuss a ...

Dirk Sauer Oversees Novartis’ Promising And Productive Ophthalmic Pipeline from 2014-10-13T00:00

As Global Head of Development Franchise Ophthalmics at Novartis, Dirk Sauer has overseen the development of Novartis’ blockbuster Lucentis. Now, his focus is on the pharmaceutical gi-ant’s pipeline...

Gobiquity Goes Big In Mobile Imaging Diagnostics from 2014-10-07T00:00

Gobiquity CEO Michael Brownell breaks down the mobile ophthalmology market from the viewpoint of a start-up that’s set to change how kids are diagnosed with amblyopia, the number one cause of visio...

Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma from 2014-09-29T00:00

Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of th...

Slade Discusses the Opportunities, and Challenges, of New Technology. from 2014-09-22T00:00

Throughout his career, Stephen Slade, MD, has been an early adopter of new ophthalmic technologies, being among the first to use LASIK, and femtosecond lasers in cataract removal. As a seasoned ear...

Hear How Avedro’s Muller Is Building A Cross-Linking Powerhouse from 2014-09-15T00:00

CEO David Muller, maps out Avedro’s designs to dominate the corneal cross-linking market and potentially change the game of vision correction.

Ophthalmology Is A “Leading Franchise” At InterWest from 2014-09-09T00:00

OIS Co-Chair, Gil Kliman, MD, Managing Director at InterWest Partners, delivers insight on his firm’s decision to concentrate on ophthalmology 15 years ago and shares the many lessons he’s learned ...

Lindstrom: Ophthalmologists Facing Both Opportunity And Pressure from 2014-09-02T00:00

Richard L. Lindstrom, MD, a long-time supporter of ophthalmology start-ups, looks ahead at the challenges facing physicians and investors as they work to meet the growing demand for ophthalmic trea...

Cunningham: Strong Signs Ahead For Ophthalmology Innovation from 2014-08-25T00:00

OIS Co-Chair, Emmett T. Cunningham, Jr., MD, recounts the origin of the Ophthalmology Inno-vation Summits and his time at the formative Eyetech Pharmaceuticals, while sharing in earnest his hopes f...

Donnenfeld Bullish on Ophthalmic Innovation from 2014-08-18T00:00

Eric Donnenfeld, MD, former president of ASCRS, explains technology has profoundly changed how opthalmology is delivered. He also shares some of his priority issues while he was president of the AS...

Link Says Versant's Eyes Will Be on Ophthalmology from 2014-08-12T00:00

Bill Link, Managing Director at Versant Ventures, explains why opthalmology will continue to be a pillar for Versant's new fund. He also gives helpful advice to entrepreneurs and physicians lo...

Mazzo Muses on the FDA, Google and Failing Fast from 2014-08-04T00:00

Jim Mazzo, former head of AMO and recent chairman of AdvaMed, offers his insights on why ophthalmology remains a standout sector in life sciences and what investors and entrepreneurs need to do to ...

Mazzo Muses on the FDA, Google and Failing Fast from 2014-08-04T00:00

Jim Mazzo, former head of AMO and recent chairman of AdvaMed, offers his insights on why ophthalmology remains a standout sector in life sciences and what investors and entrepreneurs need to do to ...

Mazzo Muses on the FDA, Google and Failing Fast from 2014-08-04T00:00

Jim Mazzo, former head of AMO and recent chairman of AdvaMed, offers his insights on why ophthalmology remains a standout sector in life sciences and what investors and entrepreneurs need to do to ...